11 April 2018

Director/PDMR Dealing

The Company announces that it was notified on 10 April that David Evans, Chairman of the Company, has purchased 3,142,857 ordinary shares in the Company ("Ordinary Shares") at 2.75 pence per Ordinary Share.

Following the transaction, David Evans' total beneficial holding in the Company has increased to 42,537,411 Ordinary Shares representing 13.11 per cent. of the issued ordinary share capital of the Company.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name David Evans
2 Reason for the notification
a) Position/status Chairman
b) Initial notification / Amendment Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Collagen Solutions Plc
b) LEI 213800IFY1CVGRGETL95
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Identification code
Ordinary shares of 1p each

ISIN Code: GB00B94T6Y14
b) Nature of the transaction Purchase of shares
c) Price(s) and volume(s)
Price(s) Volume(s)
2.75p per share 3,142,857
d) Aggregated information
- Aggregated volume
- Price

N/A - single transaction
e) Date of the transaction 10 April 2018
f) Place of the transaction London Stock Exchange

 

About Collagen Solutions:

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic, an osteochondral scaffold for repairing cartilage defects in the knee. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

For additional information on Collagen Solutions, please visit: www.collagensolutions.com

 

Enquiries: 

Collagen Solutions Plc
Jamal Rushdy, Chief Executive Officer
Hilary Spence, Chief Financial Officer
Contact via Lisa Baderoon
Lisa Baderoon, Head of Investor Relations Tel: +44 (0) 7721 413 496 or lisa.baderoon@collagensolutions.com
   
Cenkos Securities plc (Nominated Adviser and Broker)
Stephen Keys
Steve Cox
Callum Davidson
Tel: 0207 397 8900
   
Walbrook PR
Anna Dunphy
Helen Cresswell
Tel: +44 (0) 20 7933 8780 or collagen@walbrookpr.com
Mob: +44 (0) 7876 741 001